Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmasset started screening patients in an international Quantum Phase 2b trial to evaluate PSI-7977 and PSI-938 as a treatment for chronic hepatitis C (HCV).
Subscribe to our email newsletter
Quantum trial will evaluate interferon-free regimens of PSI-7977 400mg QD and PSI-938 300mg QD with and without ribavirin over 12 or 24 weeks in patients with HCV who have not been treated previously.
The trial expects to recruit around 450 patients with chronic HCV of all viral genotypes who have not been treated previously.
Pharmasset chief medical officer Michelle Berrey said the Quantum trial is the first interferon-free, all-nucleotide study with an SVR endpoint.
"The ability to include all HCV genotypes was supported by data from the Nuclear study and the interferon free arms of the Electron trial," Berrey said.